A review of binimetinib for the treatment of mutant cutaneous melanoma | Zendy

Peter Koelblinger | Zendy; Joëlle Dornbierer | Zendy; Reinhard Dummer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A review of binimetinib for the treatment of mutant cutaneous melanoma

Author(s) -

Peter Koelblinger,

Joëlle Dornbierer,

Reinhard Dummer

Publication year - 2017

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2017-0170

Subject(s) - medicine , neuroblastoma ras viral oncogene homolog , melanoma , targeted therapy , metastatic melanoma , mek inhibitor , trametinib , oncology , immunotherapy , mapk/erk pathway , cancer research , dermatology , cancer , kinase , kras , colorectal cancer , biology , microbiology and biotechnology

Although significant progress has been made in the treatment of unresectable or metastatic melanoma, at least half of all advanced melanoma patients eventually progress and pass away due to their disease. In particular, patients with NRAS-mutated melanoma still face limited therapeutic options, with immunotherapy being the current treatment type of choice. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. The results of a recent Phase III trial rendered binimetinib the first targeted therapy agent to significantly improve progression-free survival in NRAS-mutated melanoma. This review will summarize the development and clinical data of binimetinib in melanoma in general and also explore the potential future role of this substance as single agent or combination therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research